Vanguard Capital Management’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.36M Sell
2,284,882
-1,552
-0.1% -$7.33K ﹤0.01% 2799
2026
Q2
$11.4M Sell
2,286,434
-1,907
-0.1% -$9.6K ﹤0.01% 2738
2026
Q1
$12.1M Buy
+2,288,341
New +$11.7M ﹤0.01% 2627

Other funds holding IMRX

Vanguard Capital Management's IMRX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Immuneering (IMRX) stake by 0.07% in Q3 2026, selling an estimated $7.33K and leaving 2,284,882 shares worth $9.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Vanguard Capital Management first reported a position in IMRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.1M in Q1 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Vanguard Capital Management held 2,284,882 shares of Immuneering worth $9.36M as of Q3 2026.
  • Vanguard Capital Management sold 1,552 Immuneering shares in Q3 2026, an estimated $7.33K.
  • Immuneering made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2799 holding.
  • Vanguard Capital Management first reported a position in Immuneering in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Immuneering position peaked at $12.1M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.